AKI After PCI: Optimizing Contrast Selection for Real‑World Prevention-Slides: Iso-osmolar Contrast Agents: Data and Practice, Dr. Mixon

Slides: Iso-osmolar Contrast Agents: Data and Practice, Dr. Mixon

Pdf Summary

This presentation reviews whether iso-osmolar contrast agents, especially iodixanol (Visipaque), reduce contrast-induced acute kidney injury (CI-AKI) compared with low-osmolar contrast agents (LOCM) in high-risk patients.<br /><br />It begins with a clinical case of an elderly woman with NSTEMI and impaired renal function, asking whether a specific contrast choice can lower kidney risk. Contrast agents are categorized by osmolality and structure, with high-osmolar agents largely abandoned and modern practice focused on LOCM vs iodixanol.<br /><br />The evidence is mixed. Early trials such as NEPHRIC suggested iodixanol might reduce CI-AKI compared with iohexol in high-risk diabetic patients with renal dysfunction. Some other studies showed similar or modestly better outcomes with iodixanol, especially in certain high-risk groups.<br /><br />However, larger meta-analyses found no overall significant advantage of iodixanol over all LOCM. Any apparent benefit was mainly driven by comparisons against iohexol and possibly ioxaglate, not against other modern LOCM such as iopamidol, ioversol, or iopromide. Thus, iodixanol does not consistently outperform all low-osmolar agents.<br /><br />Guidelines have evolved accordingly. Earlier PCI guidelines favored iso-osmolar contrast in CKD, but more recent recommendations state that data are insufficient to prefer iso-osmolar over modern low-osmolar agents.<br /><br />The main prevention strategies for CI-AKI remain: identify high-risk patients, optimize hydration, minimize contrast volume, and manage other modifiable risk factors. Iodixanol may be reasonable in very high-risk patients, but it is not clearly required and is more expensive.

Keywords

iso-osmolar contrast

iodixanol

Visipaque

contrast-induced acute kidney injury

CI-AKI

low-osmolar contrast agents

LOCM

iodixanol meta-analysis

hydration

chronic kidney disease